This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial activity against the following bacteria in vitro: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes and other Enterobacter species, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. Norfloxacin also has antibacterial activity against multi-drug resistant bacteria in vitro. It also has good antibacterial effects on penicillin-resistant Neisseria gonorrhoeae, Haemophilus influenzae and Moraxella catarrhalis. Norfloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

Inhibit the activity of angiotensin converting enzyme, reduce the level of angiotensin II, reduce the secretion of aldosterone, dilate arteries and veins, achieve a hypotensive effect and reduce the preload and afterload of the heart to improve heart function

Increase the excretion of sodium chloride by the kidneys to play a diuretic role, reduce blood volume, and exert a hypotensive effect

It has the effect of competitively blocking the binding of histamine to H2 receptors and inhibiting the action of gastric acid, which is 5 to 12 times that of cimetidine in terms of moles. Continuous oral administration for 5 and 26 weeks showed a good non-toxic dose range, and no carcinogenic effect was found in long-term animal experiments.